Calliditas Therapeutics Ab Revenue Growth Rates (CALT), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Calliditas Therapeutics Ab  (NASDAQ: CALT)
 

CALT's Revenue Growth by Quarter and Year

Calliditas Therapeutics Ab's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CALT Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
4th Quarter December -
3rd Quarter September -
2nd Quarter June 52.36
1st Quarter March 129.24
FY 181.60





CALT Revenue second quarter 2024 Y/Y Growth Comment
Calliditas Therapeutics Ab in the second quarter 2024 achieved Revenue of $ 52.36 millions compare to recorded in same quarter a year ago.

According to the results reported in the second quarter 2024, Calliditas Therapeutics Ab achieved the best Revenue growth in Major Pharmaceutical Preparations industry. While Calliditas Therapeutics Ab' s Revenue no change of 0% ranks overall at the positon no. in the second quarter 2024.


CALT Revenue ( Y/Y Growth %) 2024
 2023 2022 2021
4th Quarter December - - - -
3rd Quarter September - 292.64 % - -
2nd Quarter June - - - -
1st Quarter March 49.74 % - - -
FY   - 844.39 % - -

Financial Statements
Calliditas Therapeutics Ab's second quarter 2024 Revenue $ 52.36 millions CALT's Income Statement
Calliditas Therapeutics Ab's second quarter 2023 Revenue $ 0.00 millions Quarterly CALT's Income Statement


CALT Revenue (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
4th Quarter December - - - -
3rd Quarter September - - 22.33 % -
2nd Quarter June -59.48 % - - -
1st Quarter March - - - -
FY (Year on Year)   - 844.39 % - -


Back to CALT Growth rate Comparisons >> Back to CALT Growth rate Comparisons >>


Revenue second quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
(Dec 31 2023)  
Revenue second quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
(Dec 31 2023)  

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Calliditas Therapeutics Ab's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
22.32 % -69.42 % -100 %
0  


CALT's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2024 Calliditas Therapeutics Ab disclosed fall in Revenue from the first quarter by -59.48% to $ 52.36 millions, from $ 129.24 millions achived in the previous reporting period.

Within Major Pharmaceutical Preparations industry 256 other companies have achieved higher Revenue quarter on quarter growth. While Calliditas Therapeutics Ab's Revenue growth quarter on quarter, overall rank is 4213.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #257
Healthcare Sector #667
Overall #4213
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #257
Healthcare Sector #667
Overall #4213
Revenue Q/Q Growth Statistics
High Average Low
22.32 % -69.42 % -100 %
0  


CALT's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2024 Calliditas Therapeutics Ab disclosed fall in Revenue from the first quarter by -59.48% to $ 52.36 millions, from $ 129.24 millions achived in the previous reporting period.

Within Major Pharmaceutical Preparations industry 256 other companies have achieved higher Revenue quarter on quarter growth. While Calliditas Therapeutics Ab's Revenue growth quarter on quarter, overall rank is 4213.


Calliditas Therapeutics Ab's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Dec 31 2021)		 12 Months Ending
 12 Months Ending
Cumulative Revenue 12 Months Ending $ 129.24 $ 86.31 $ 0.00 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) 49.74 % - - - -
Year on Year Revenue Growth Overall Ranking # 409 # 336 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) 49.74 % - - - -
Seq. Revenue Growth (TTM) Overall Ranking # 409 # 349 # 0 # 0 # 0


Cumulative Revenue growth Comment
With 49.74% annual Revenue growth, Calliditas Therapeutics Ab would report a record annual Revenue growth if the fiscal year would end on Dec 31 2023.

In the Healthcare sector 113 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 336 to 409.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 58
Healthcare Sector # 114
Overall # 409

Revenue TTM Y/Y Growth Statistics
High Average Low
49.74 %
 49.74 %
49.74 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 58
Sector # 114
S&P 500 # 409
Cumulative Revenue growth Comment
With 49.74% annual Revenue growth, Calliditas Therapeutics Ab would report a record annual Revenue growth if the fiscal year would end on Dec 31 2023.

In the Healthcare sector 113 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 336 to 409.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 58
Healthcare Sector # 114
Overall # 409

Revenue TTM Y/Y Growth Statistics
High Average Low
49.74 %
49.74 %
49.74 %
 






Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CALT's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue growth for the quarter ending Jun 30 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2024
Organon and Co -0.06%$ -0.062 millions
Royalty Pharma Plc-0.17%$ -0.174 millions
Repligen Corp-0.21%$ -0.207 millions
Whitehawk Therapeutics Inc -0.37%$ -0.371 millions
3m Company-0.45%$ -0.446 millions
T2 Biosystems Inc -0.61%$ -0.611 millions
Hcw Biologics Inc -0.63%$ -0.635 millions
Enhabit Inc -0.65%$ -0.648 millions
Sonoma Pharmaceuticals Inc -1.05%$ -1.050 millions
Encision Inc -1.36%$ -1.358 millions
Vaso Corporation-1.40%$ -1.399 millions
Teladoc Health Inc -1.53%$ -1.527 millions
Zimvie Inc -1.55%$ -1.549 millions
Alpha Pro Tech Ltd -1.65%$ -1.645 millions
Novavax inc -2.11%$ -2.107 millions
Agile Therapeutics Inc-2.23%$ -2.232 millions
Fresenius Medical Care Ag-2.33%$ -2.330 millions
Avantor Inc -2.36%$ -2.357 millions
Aspira Women s Health inc -2.81%$ -2.810 millions
Viatris Inc -3.11%$ -3.113 millions
Catheter Precision Inc -3.13%$ -3.125 millions
Nrc Health-3.15%$ -3.153 millions
Akoya Biosciences Inc -3.16%$ -3.158 millions
Neuronetics Inc -3.55%$ -3.547 millions
Mettler toledo International Inc -3.60%$ -3.601 millions
Prestige Consumer Healthcare Inc -4.18%$ -4.181 millions
Dentsply Sirona Inc -4.28%$ -4.280 millions
Waters Corporation-4.33%$ -4.327 millions
Accelerate Diagnostics Inc -4.39%$ -4.394 millions
Envista Holdings Corporation-4.50%$ -4.499 millions


About Calliditas Therapeutics Ab Revenue Growth Rates (CALT), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Calliditas Therapeutics Ab (CIK 1795579).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001410578-24-000528
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Calliditas Therapeutics Ab’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.